Iovance Biotherapeutics (IOVA) Return on Capital Employed (2011 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Return on Capital Employed of 45.97% for Q1 2026, up 290.0% year-over-year from 11.79% in Q1 2025, and up 12.16% quarter-over-quarter from 52.34% in Q4 2025.
Iovance Biotherapeutics (IOVA) Return on Capital Employed (2011 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Return on Capital Employed for 15 consecutive years, with 45.97% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 290.0% year-over-year to 45.97%; the TTM figure through Mar 2026 stood at 45.97% (up 290.0% YoY), while the FY2025 annual figure was 52.15%, up 252.0% from the prior year.
- Return on Capital Employed climbed to 45.97% in Q1 2026 per IOVA's latest filing, from 52.34% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 45.97% in Q1 2026 and bottomed at 78.39% in Q3 2022.
- Historically, Return on Capital Employed has averaged 60.05% across 5 years, with a median of 61.76% in 2023.
- Annual changes were most pronounced in 2022 — Return on Capital Employed tumbled 3822 bps — and 2023, when it surged 1587 bps.
- Iovance Biotherapeutics' Return on Capital Employed stood at 77.68% in 2022, then increased by 16 bps to 65.23% in 2023, then advanced by 3 bps to 63.01% in 2024, then climbed by 17 bps to 52.34% in 2025, then climbed by 12 bps to 45.97% in 2026.
- Business Quant data shows IOVA's Return on Capital Employed at 45.97% in Q1 2026, 52.34% in Q4 2025, and 53.37% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn | -37.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -37.03% |
| Mar 31, 2026 | -45.97% |
| Dec 31, 2025 | -52.34% |
| Sep 30, 2025 | -53.37% |
| Jun 30, 2025 | -50.83% |
| Mar 31, 2025 | -48.88% |
| Mar 31, 2024 | -63.01% |
| Dec 31, 2023 | -65.23% |
| Sep 30, 2023 | -62.53% |
| Jun 30, 2023 | -60.99% |
| Mar 31, 2023 | -63.62% |
| Dec 31, 2022 | -77.68% |
| Sep 30, 2022 | -78.39% |
| Jun 30, 2022 | -63.72% |
| Mar 31, 2022 | -54.19% |
| Dec 31, 2021 | -48.01% |
| Sep 30, 2021 | -40.17% |
| Jun 30, 2021 | -38.39% |
| Mar 31, 2021 | -37.86% |
| Dec 31, 2020 | -36.35% |